Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | TXNRD1 | Q16881 | 6/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 6/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 6/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305805 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL1056613 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL398655 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100895 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100890 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Ammonia Solution, Strong SCHEMBL19100618 | 0.98 | ALDH1A1 (0.61) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Trimethylammonium SCHEMBL19100739 | 0.94 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Trimethylammonium SCHEMBL19100769 | 0.94 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| Trimethylammonium SCHEMBL19100741 | 0.94 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNATDP1TXNRD1 | |
| SCHEMBL7623530 | 0.94 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNATDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118814522-B | Preparation method and application of base paper of peroxyacetic acid detection test paper | HANGZHOU SPECIAL PAPER Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-118814522-A | Preparation method and application of base paper of peroxyacetic acid detection test paper | 杭州特种纸业有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118791649-A | Synthesis method of hydroxyl-terminated thioalkyl beta-cyclodextrin sulfate derivative | 内蒙古大学 | 2024-10-18 | — | — | CN | claimed |
| CN-116549733-A | Decellularized vascular stent with anticoagulation and endothelialization promoting functions and preparation method thereof | 新乡医学院 | 2023-08-08 | — | — | CN | claimed |
| US-11291750-B2 | Hydrogel condom | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2022-04-05 | — | — | US | claimed |
| CN-109073641-B | Immunological assay using sulfated polysaccharides | 美迪恩斯生命科技株式会社 | 2022-03-11 | — | — | CN | claimed |
| US-20210330695-A1 | TREATMENT OF PAIN WITH POLYSULFATED POLYSACCHARIDES | Paradigm Biopharmaceuticals Ltd. (AU) | 2021-10-28 | — | — | US | claimed |
| CN-108690022-B | Fluorinated integrin antagonists | 赛弗卢尔生命科学公司 | 2021-08-17 | — | — | CN | claimed |
| US-20210015849-A1 | TREATMENT OF BONE MARROW EDEMA (OEDEMA) WITH POLYSULFATED POLYSACCHARIDES | PARADIGM HEALTH SCIENCES PTY LTD (AU) | 2021-01-21 | — | — | US | claimed |
| EP-3661524-A1 | TREATMENT OF BONE MARROW PATHOLOGIES WITH POLYSULFATED POLYSACCHARIDES | Paradigm Biopharmaceuticals Limited (AU) | 2020-06-10 | — | — | EP | claimed |
| US-20030027791-A1 | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins | WYETH | 2003-02-06 | — | — | US | claimed |
| WO-2003002153-A1 | COMPOSITION AND METHOD FOR REDUCING ADVERSE INTERACTIONS BETWEEN PHENOTHIAZINE DERIVATIVES AND PLASMA USING CYCLODEXTRINS | WYETH (US) | 2003-01-09 | — | — | WO | claimed |
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | LEC TEC CORPORATION | 2002-12-19 | — | — | US | claimed |
| US-20020146830-A1 | Transfecting polynucleotide into cells; obtain transfection mixture, incubate with solublize in cholesterol mixture, expose with cells, recover transfected cells | GENECURE PTE LTD (SG) | 2002-10-10 | — | — | US | claimed |
| EP-1208218-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF PHARMACEUTICAL AGENTS | Genecure Pte Ltd (SG) | 2002-05-29 | — | — | EP | claimed |
| WO-2001015755-A2 | METHODS AND COMPOSITIONS FOR DELIVERY OF PHARMACEUTICAL AGENTS | GENECURE PTE LTD (SG) | 2001-03-08 | — | — | WO | claimed |
| EP-1061530-A1 | Method for preparing intrinsically conductive co-polymers and co-polymer compositions prepared therefrom | ROHM AND HAAS COMPANY (US) | 2000-12-20 | — | — | EP | claimed |
| US-5681380-A | MIXTURE OF COLORANT, AN ARYLKETOALKENE COMPOUND AND A LIQUID VEHICLE | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 1997-10-28 | — | — | US | claimed |
| EP-0447351-B1 | Medicament for retaining ophthalmological agents in ocular tissues and method for its production | CHILDRENS MEDICAL CENTER (US) | 1996-01-10 | — | — | EP | claimed |
| US-5459078-A | Quantitative analysis of digoxin and immobilization | ABBOTT LABORATORIES (US) | 1995-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020192273-A1 | Therapeutic patch useful for the treatment of hemorrhoids | PTGIR, PLOD3, PTGIS | ALDH1A1 1131/4885TSHR 4136/4885LMNA 1538/4885 |
| US-20030027791-A1 | Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins | SORD, CYP3A5, CYP3A43 | ALDH1A1 3335/4885TSHR 4202/4885LMNA 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.